More importantly, if correcting disrupted ER-mitochondria signaling and VAPB-PTPIP51 tethering is to be a valid drug target for ALS, it is essential we know whether these features are actually damaged in human disease. This evidence concerns the gene RMDN3 and amyotrophic lateral sclerosis.